Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses.

Numerous studies have reported that monoclonal antibody (mAb) FMC7 detects an antigen present on only a subset of circulating B lymphocytes. In particular, this mAb may distinguish typical B-cell chronic lymphocytic leukemia (FMC7 negative) from other types of B-cell non-Hodgkin lymphoma (B-NHL; FMC7 positive). We treated patients with B-NHL with Rituxan, a chimeric CD20 mAb, and observed abrogation of staining not only with prototype CD20 mAb B-1 but also with mAb FMC7. To investigate the relation between antigens CD20 and FMC7, we performed mutual blocking studies that showed mutual inhibition of FMC7 and CD20. In addition, FMC7 modulated CD23 expression and confirmed the presence of mAb B-1 in B-lymphoblastoid cell lines CESS and JVM. Transient transfection of myeloid cell line K562 with plasmid containing CD20-encoding cDNA produced de novo expressions of CD20 and FMC7. Our data indicate that FMC7 binds to a particular conformation of the CD20 antigen, probably to a multimeric CD20 complex. We assume that FMC7 stains positively only when CD20 antigen is present in high densities and in the postulated multimeric complex formation.

[1]  D. Huhn,et al.  Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma. , 2000, Cytometry.

[2]  J. D'hautcourt,et al.  Mean fluorescence intensity of dual stained cells. , 1999, Cytometry.

[3]  R C Braylan,et al.  FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. , 1998, Cytometry.

[4]  Joseph A. DiGiuseppe,et al.  Clinical utility of flow cytometry in the chronic lymphoid leukemias. , 1998, Seminars in oncology.

[5]  D. Catovsky,et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.

[6]  W. Di Berardino,et al.  CD20 monoclonal antibodies stimulate extracellular cleavage of the low affinity receptor for IgE (Fc epsilon RII/CD23) in Epstein-Barr-transformed B cells. , 1994, The Journal of biological chemistry.

[7]  H. Kantarjian,et al.  Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. , 1994, American journal of clinical pathology.

[8]  R. Frizzell,et al.  Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes , 1993, The Journal of cell biology.

[9]  C. Geisler,et al.  Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. , 1991, Blood.

[10]  B. Zegers,et al.  Evidence that FMC7 is a human B cell differentiation antigen. , 1990, Immunology letters.

[11]  J. V. van Dongen,et al.  Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. , 1990, The American journal of pathology.

[12]  T. Tedder,et al.  Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). , 1989, Journal of immunology.

[13]  A. Bloem,et al.  Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7. , 1988, Journal of immunology.

[14]  J. Melo,et al.  Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules. , 1987, Disease markers.

[15]  C. S. Scott,et al.  Membrane phenotypic studies in B cell lymphoproliferative disorders. , 1985, Journal of clinical pathology.

[16]  H. Zola,et al.  The antigen of mature human B cells detected by the monoclonal antibody FMC7: studies on the nature of the antigen and modulation of its expression. , 1984, Journal of immunology.

[17]  H. Zola,et al.  Maturation of human B lymphocytes--studies with a panel of monoclonal antibodies against membrane antigens. , 1983, Clinical and experimental immunology.

[18]  D. Catovsky,et al.  Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7 , 1981 .

[19]  H. Zola,et al.  Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. , 1981, Journal of immunology.

[20]  H. Saito,et al.  Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Zola.  Human B Cells: Is FMC7 a Marker for Relatively Mature B Cells or Does It Define a Population Equivalent to the LyB5-Negative Mouse B Cells? , 1986 .

[22]  H. Zola,et al.  The Human B Cell Lineage Studied with Monoclonal Antibodies , 1984 .